In a large study published on the The Lancet Respiratory Medicine on October 18, 2024, epidemiological and vital registry data were analysed to estimate the non-fatal and fatal burden of pulmonary arterial hypertension, using standard GBD (Global Burden of Diseases) modelling approaches.
🔹 The aim of this investigation was to better characterise the worldwide epidemiology of PAH including regional variation, place this in context relative to other disease entities, and highlight areas of uncertainty that necessitate further study. This effort was specifically focused on PAH.
🔹 The GBD study is the largest and most comprehensive effort to quantify health loss across places and over time, so health systems can be improved and disparities eliminated. It estimates disease burden for 371 diseases and injuries and 88 risk factors in 204 countries and territories. The GBD It is coordinated by the Institute for Health Metrics and Evaluation.
The full article is available at this link on The Lancet Respiratory Medicine
Citation
Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021Leary, Peter J et al.The Lancet Respiratory Medicine, Volume 0, Issue 0
Photo credit Lara Jameson at Pexels